> Details

Johnson, Douglas B.; Atkins, Michael B.; Hennessy, Cassandra; Wise-Draper, Trisha; Heilman, Hannah; Awosika, Joy; Bakouny, Ziad; Labaki, Chris; Saliby, Renee Maria; Hwang, Clara; Singh, Sunny R. K.; Balanchivadze, Nino; Friese, Christopher R.; Fecher, Leslie A.; Yoon, James J.; Hayes-Lattin, Brandon; Bilen, Mehmet A.; Castellano, Cecilia A.; Lyman, Gary H.; Tachiki, Lisa; Shah, Sumit A.; Glover, Michael J.; Flora, Daniel B.; Wulff-Burchfield, Elizabeth; [...]

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
  • Contributor: Johnson, Douglas B.; Atkins, Michael B.; Hennessy, Cassandra; Wise-Draper, Trisha; Heilman, Hannah; Awosika, Joy; Bakouny, Ziad; Labaki, Chris; Saliby, Renee Maria; Hwang, Clara; Singh, Sunny R. K.; Balanchivadze, Nino; Friese, Christopher R.; Fecher, Leslie A.; Yoon, James J.; Hayes-Lattin, Brandon; Bilen, Mehmet A.; Castellano, Cecilia A.; Lyman, Gary H.; Tachiki, Lisa; Shah, Sumit A.; Glover, Michael J.; Flora, Daniel B.; Wulff-Burchfield, Elizabeth; [...]
  • imprint: Springer Science and Business Media LLC, 2023
  • Published in: BMC Cancer
  • Language: English
  • DOI: 10.1186/s12885-023-10708-6
  • ISSN: 1471-2407
  • Keywords: Cancer Research ; Genetics ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Introduction</jats:title> <jats:p>COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors. </jats:p> </jats:sec>
  • Access State: Open Access